Inhibition of NF-κB-induced inflammatory responses by angiotensin II antagonists in aged rat kidney

In this study, we explored the mechanisms by which the angiotensin converting enzyme inhibitor (ACEI), enalapril, and the Ang II receptor blocker (ARB), losartan suppress oxidative stress and NF-κB activation-induced inflammatory responses in aged rat kidney. The experimentations were carried out utilizing aged (24-month-old) Brown Norway×Fischer 344 (F1) male rats which were randomized into 3 groups and administered enalapril (40 mg/kg), losartan (30 mg/kg) or placebo for 6 months (daily p.o.). The level of reactive species (RS), peroxynitrite (ONOO(-)), GSH/GSSG and lipid peroxidation were measured. The activity of the pro-inflammatory transcription factor NF-κB, and gene expression of proteins in upstream signaling cascades were measured by electro-mobility shift assay (EMSA) and Western blotting. Enalapril and losartan differentially attenuated redox imbalance and the redox-sensitive transcription factor, the NF-κB pathway. Furthermore, stimulation of the NF-κB activation pathway by phosphorylation of p65 was attenuated by both compounds. Moreover, mediation of phosphorylation of p65 by phosphorylation of IκB kinase αβ (IKKαβ) and mitogen- and stress-activated protein kinase-1 (MSK-1), were also inhibited by enalapril and losartan. Finally, both compounds also lowered expression of NF-κB-dependent inflammatory genes, such as cyclooxygenase-2 (COX-2), and inducible NO synthase (iNOS). Only losartan lowered levels of 5-lipoxygenase (5-LOX). These findings indicate that enalapril and losartan differentially suppress inflammatory responses via inhibition of oxidative stress-induced NF-κB activation in aged rat kidney.

[1]  N. Vaziri,et al.  Intra-Renal Angiotensin II/AT1 Receptor, Oxidative Stress, Inflammation, and Progressive Injury in Renal Mass Reduction , 2007, Journal of Pharmacology and Experimental Therapeutics.

[2]  S. Saleh,et al.  Protective Effects of the Angiotensin II Receptor Blocker Losartan on Cisplatin-Induced Kidney Injury , 2009, Chemotherapy.

[3]  G. Remuzzi,et al.  Angiotensin receptors as determinants of life span , 2009, Pflügers Archiv - European Journal of Physiology.

[4]  A. Hoffmann,et al.  The I (cid:1) B –NF-(cid:1) B Signaling Module: Temporal Control and Selective Gene Activation , 2022 .

[5]  C. Finch,et al.  The Demographic and Biomedical Case for Late-Life Interventions in Aging , 2010, Science Translational Medicine.

[6]  M. Merville,et al.  Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation , 2005 .

[7]  G. Wolf,et al.  Angiotensin II-induced reactive oxygen species and the kidney. , 2007, Journal of the American Society of Nephrology : JASN.

[8]  R. Carey Angiotensin receptors and aging. , 2007, Hypertension.

[9]  S Jay Olshansky,et al.  Aging in America in the twenty-first century: demographic forecasts from the MacArthur Foundation Research Network on an Aging Society. , 2009, The Milbank quarterly.

[10]  S. Rajagopalan,et al.  Role of superoxide in angiotensin II-induced but not catecholamine-induced hypertension. , 1997, Circulation.

[11]  R W Alexander,et al.  Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. , 1994, Circulation research.

[12]  J. Francis,et al.  Cross-talk between cytokines and renin-angiotensin in hypothalamic paraventricular nucleus in heart failure: role of nuclear factor-kappaB. , 2008, Cardiovascular research.

[13]  S. Ghosh,et al.  Phosphorylation of NF-kappa B p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. , 1998, Molecular cell.

[14]  W R Taylor,et al.  Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. , 1998, Hypertension.

[15]  R. Santos,et al.  Altered cardiovascular responses to chronic angiotensin II infusion in aged rats , 2005, Regulatory Peptides.

[16]  D. Siegel,et al.  Regulation of NF-kB in multiple myeloma: therapeutic implications. , 2004, Clinical advances in hematology & oncology : H&O.

[17]  E. Mervaala,et al.  Angiotensin II and vascular inflammation. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[18]  I. Stella,et al.  Protective effect of the inhibition of the renin–angiotensin system on aging , 2005, Regulatory Peptides.

[19]  Byung Pal Yu,et al.  Molecular inflammation hypothesis of aging based on the anti‐aging mechanism of calorie restriction , 2002, Microscopy research and technique.

[20]  F. Inserra,et al.  Cardiovascular changes by long-term inhibition of the renin-angiotensin system in aging. , 1995, Hypertension.

[21]  J. Pesquero,et al.  Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. , 2009, Biochemical pharmacology.

[22]  B. Brenner,et al.  Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass. , 1985, The Journal of clinical investigation.

[23]  Y. Tomino,et al.  Combination Effects of Enalapril and Losartan on Lipid Peroxidation in the Kidneys of KK-Ay/Ta Mice , 2009, Nephron Experimental Nephrology.

[24]  T. Oyama,et al.  Activity and responsiveness of the renin-angiotensin system in the aging rat. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[25]  Chul-woo Yang,et al.  Combined Effects of Losartan and Pravastatin on Interstitial Inflammation and Fibrosis in Chronic Cyclosporine-Induced Nephropathy , 2005, Transplantation.

[26]  S. Anton,et al.  Molecular inflammation: Underpinnings of aging and age-related diseases , 2009, Ageing Research Reviews.

[27]  J. Rutledge,et al.  Enalapril attenuates angiotensin II-induced atherosclerosis and vascular inflammation. , 2005, Atherosclerosis.

[28]  I. Stella,et al.  Changes seen in the aging kidney and the effect of blocking the renin—angiotensin system , 2009, Therapeutic advances in cardiovascular disease.

[29]  A. Cueto-Manzano,et al.  Is Systemic Inflammation of Hemodialysis Patients Improved With the Use of Enalapril? Results of a Randomized, Double-Blinded, Placebo-Controlled Clinical Trial , 2010, ASAIO journal.

[30]  F. Rey,et al.  The Reactive Adventitia: Fibroblast Oxidase in Vascular Function , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[31]  J. Sowers,et al.  Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. , 2008, American journal of physiology. Endocrinology and metabolism.

[32]  S. Ishida [Lifestyle-related diseases and anti-aging ophthalmology: suppression of retinal and choroidal pathologies by inhibiting renin-angiotensin system and inflammation]. , 2009, Nippon Ganka Gakkai zasshi.

[33]  S. Ghosh,et al.  The Phosphorylation Status of Nuclear NF-ΚB Determines Its Association with CBP/p300 or HDAC-1 , 2002 .

[34]  H. Chung,et al.  Modulation of PPAR in aging, inflammation, and calorie restriction. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[35]  A. Fujimura,et al.  Effect Of Enalapril On Diabetic Nephropathy In Oletf Rats: The Role Of An Anti‐Oxidative Action In Its Protective Properties , 2001, Clinical and experimental pharmacology & physiology.

[36]  Keiko Takahashi,et al.  Angiotensin II receptor antagonist attenuates expression of aging markers in diabetic mouse heart. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[37]  W. Ambrosius,et al.  Angiotensin-converting enzyme inhibition, body composition, and physical performance in aged rats. , 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

[38]  A. D. de Grey The case for prioritizing research on late-onset life-extension interventions in mammals. , 2007, Rejuvenation research.

[39]  B. Croker,et al.  Protection against age-dependent renal injury in the F344xBrown Norway male rat is associated with maintained nitric oxide synthase , 2011, Mechanisms of Ageing and Development.